Immunotech Biopharm's stock plummeted 5.51% during Monday's intraday trading session.
The sharp decline followed the company's announcement of its 2025 financial results, which showed a widening attributable loss of 230.8 million yuan, compared to a loss of 186.9 million yuan in 2024. Loss per share increased to 0.42 yuan from 0.35 yuan in the prior year.
The company reported no revenue for the year, while other income also decreased to 20.5 million yuan from 33.8 million yuan in 2024, contributing to investor concerns about its financial performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.